(All fields required)
Please enter a valid email.
Please enter your name.
Midkine (MDK) activates the PI3K pathway and induces anti-apoptotic activity, in turn enhancing the survival of tumors.
Therefore, the inhibition of MDK is considered a potential strategy for cancer therapy. We have identified a novel small molecule compound (iMDK) that targets MDK. iMDK inhibited the cell growth of H441 lung adenocarcinoma cells that harbor an oncogenic KRAS mutation and H520 squamous cell lung cancer cells, but did not affect the growth of MDK-negative adenocarcinoma cells or normal lung cells. Inhibition of MDK with iMDK provides a potential therapeutic approach for the treatment of lung cancers that are driven by MDK.
For an in-depth market overview, please click here.
Hao H, et al. (2013) Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer. PLOS One. Vol. 8, Issue 8. e71093.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center